MXPA03009660A - Tetrahidroisoquinolinas sustituidas para su uso en el tratamiento de enfermedades inflamatorias. - Google Patents

Tetrahidroisoquinolinas sustituidas para su uso en el tratamiento de enfermedades inflamatorias.

Info

Publication number
MXPA03009660A
MXPA03009660A MXPA03009660A MXPA03009660A MXPA03009660A MX PA03009660 A MXPA03009660 A MX PA03009660A MX PA03009660 A MXPA03009660 A MX PA03009660A MX PA03009660 A MXPA03009660 A MX PA03009660A MX PA03009660 A MXPA03009660 A MX PA03009660A
Authority
MX
Mexico
Prior art keywords
compounds
linkage
oxides
optionally substituted
ester prodrugs
Prior art date
Application number
MXPA03009660A
Other languages
English (en)
Inventor
Victor Harris Neil
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0113708A external-priority patent/GB0113708D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of MXPA03009660A publication Critical patent/MXPA03009660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se enfoca a compuestos fisiologicamente activos de la formula (I): en donde R1 representa arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, R3-NH-Ar1-L2- o bien R3-NH-C(=0) -NH-Ar2-L2; R3 representa arilo o heteroarilo; Ar1 representa un sistema de anillo biciclico de 8 a 10 miembros saturado, parcialmente saturado o totalmente insaturado que contiene por lo menos un heteroatomo seleccionado entre O, S o N; Ar2 representa arildiilo o heteroarildiilo; L1 representa un enlace, por ejemplo un enlace alquileno; L2 representa un enlace de cadena alquileno; R2 representa hidrogeno, halogeno, alquilo C1-4 o alcoxi C1-4; y Y es carboxi o un bioisostero de acido; pero excluyendo compuestos en donde un atomo de oxigeno, nitrogeno o azufre esta unido directamente a un enlace multiple carbono-carbono de un residuo de alquenileno o alquinileno; y los N-oxidos correspondientes y profarmacos de esteres de los mismos, y las sales y solvatos farmaceuticamente aceptables de tales compuestos, y los N- oxidos y profarmacos de esteres de los mismos. Tales compuestos tienen propiedades farmaceuticas valiosas, en particular la capacidad de regular la interaccion de VCAM-1 y fibronectina con la integrina VLA-4 (a4¦1).
MXPA03009660A 2001-06-06 2002-06-05 Tetrahidroisoquinolinas sustituidas para su uso en el tratamiento de enfermedades inflamatorias. MXPA03009660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0113708A GB0113708D0 (en) 2001-06-06 2001-06-06 Chemical compounds
US31150201P 2001-08-10 2001-08-10
PCT/GB2002/002517 WO2002098426A1 (en) 2001-06-06 2002-06-05 Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
MXPA03009660A true MXPA03009660A (es) 2004-04-02

Family

ID=26246159

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009660A MXPA03009660A (es) 2001-06-06 2002-06-05 Tetrahidroisoquinolinas sustituidas para su uso en el tratamiento de enfermedades inflamatorias.

Country Status (13)

Country Link
US (1) US7211586B2 (es)
EP (1) EP1392306B1 (es)
JP (1) JP4583751B2 (es)
AT (1) ATE383858T1 (es)
AU (1) AU2002302783B2 (es)
CA (1) CA2449402C (es)
DE (1) DE60224664T2 (es)
DK (1) DK1392306T3 (es)
ES (1) ES2296926T3 (es)
IL (1) IL159203A0 (es)
MX (1) MXPA03009660A (es)
PT (1) PT1392306E (es)
WO (1) WO2002098426A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820160B (zh) 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
TW200536851A (en) * 2004-01-23 2005-11-16 Amgen Inc Compounds and methods of use
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体
WO2006060318A2 (en) 2004-11-30 2006-06-08 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
WO2007050124A1 (en) * 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠系统的递送
WO2010093535A1 (en) * 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
SG11201401236XA (en) * 2011-10-14 2014-05-29 Ambit Biosciences Corp Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
WO2013082000A1 (en) * 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
WO2018140876A1 (en) * 2017-01-30 2018-08-02 Biogen Ma Inc. Nrf2 activator
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2023287241A1 (ko) * 2021-07-15 2023-01-19 주식회사 휴사이온 신규한 벤즈옥사졸아민 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
DE69928667T2 (de) * 1998-06-30 2006-08-10 Pfizer Products Inc., Groton Nicht-peptidische Inhibitoren von VLA-4-abhängiger Zellbindung für die Behandlung von entzündlichen, autoimmun-und respiratorischen Krankheiten und Atemstörungen
NZ509781A (en) * 1998-08-26 2003-05-30 Aventis Pharma Ltd Quinoline or indolyl derivativees useful for modulating the inhibition of cell adhesion
WO2001021584A1 (en) * 1999-09-24 2001-03-29 Genentech, Inc. Tyrosine derivatives

Also Published As

Publication number Publication date
US20040122047A1 (en) 2004-06-24
CA2449402A1 (en) 2002-12-12
JP2005500276A (ja) 2005-01-06
WO2002098426A1 (en) 2002-12-12
US7211586B2 (en) 2007-05-01
EP1392306A1 (en) 2004-03-03
DK1392306T3 (da) 2008-05-19
PT1392306E (pt) 2008-03-07
CA2449402C (en) 2009-08-11
IL159203A0 (en) 2004-06-01
JP4583751B2 (ja) 2010-11-17
ES2296926T3 (es) 2008-05-01
ATE383858T1 (de) 2008-02-15
DE60224664T2 (de) 2009-01-08
DE60224664D1 (de) 2008-03-06
AU2002302783B2 (en) 2006-11-16
EP1392306B1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
MXPA03009660A (es) Tetrahidroisoquinolinas sustituidas para su uso en el tratamiento de enfermedades inflamatorias.
HUP0302960A2 (hu) Kemokinreceptorhoz kötődő heterociklusos vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BG108806A (en) IIb/IIIa CELL ADHESION INHIIBITORS, METHOD FOR THE PRODUCTION, PHARMACEUTCIAL COMPOSITION AND ADMINISTRATION THEREOF
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
TR199801642T2 (xx) Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
TR200100694T2 (tr) Opioid alıcı aktivitesine sahip 4,4-Biarilpiperidin türevleri
HUP0400732A2 (hu) Gyógyászatilag hatékony uridin-észterek
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
UA48937C2 (uk) Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить
ES8801245A1 (es) Un procedimiento para preparar derivados de piperidina
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
HUP0002442A2 (hu) Heterociklusos tio-észterek nitrogénen át kapcsolódó karbamid- és karbamátszármazékai, és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
DE3763863D1 (de) Substituierte tetrahydro-3-pyridincarbonsaeuren, ihre ester und amide als cholinergische mittel.
NZ210100A (en) 5h,11h-pyrrolo(2,1-c)(1,4)benzoxazepine derivatives and pharmaceutical compositons
ATE258050T1 (de) Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
TR200002808T2 (tr) İlaç olarak yararlı C11 oksimil ve hidroksilamino prostaglandinleri
DE69720966D1 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
NO980788L (no) Immunosuppressant
AP2001002314A0 (en) Substituted benzolactam compounds.
ATE278701T1 (de) Malto-oligosaccharide und deren verwendung
ES8704895A1 (es) Un metodo para preparar 1-aminoalquilamino-4-ariloxipiperidinas sustituidas
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
HUP0401597A2 (hu) Metilén-4-azaszteroidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
GEP19970838B (en) Process for obtaining 3-(methyltio, methylsulphinyl or methylsulphonyl)-4-quinolone